Friday, June 3, 2016

NantHealth Launches Molecular Testing, Decision Support Product

Culver City-based NantHealth has launched a new product, which provides molecular testing and decision support solutions for cancer patients. According to NantHealth, its new Genomic Proteomic Spectrometry Cancer or GPS Cancer product, measures the proteins in a patient's tumor tissue, and uses whole genomic and transcriptomic sequencing to help personalize chemotherapy treatment. The company said its new product provides oncologists with a detailed, molecaulr profile of a patient's cancer to help shape treatment strategies.

---